Some mutations of this oncogene, especially the Threonine 315 to Isoleucine substitution of the ABL kinase is resistant to first and second-generation tyrosine kinase inhibitors (TKIs) conventionally used in CML therapy. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.